Patents Represented by Attorney, Agent or Law Firm Paul R. Cantrell
  • Patent number: 6322998
    Abstract: The present invention provides DNA compounds that encode ACV synthetase activity of Cephalosporium acremonium. The compounds can be used to construct recombinant DNA expression vectors for a wide variety of host cells, including E. coli, Penicillium, Cephalosporium, and Aspergillus.
    Type: Grant
    Filed: October 29, 1992
    Date of Patent: November 27, 2001
    Assignee: Eli Lilly and Company
    Inventors: Cathleen A. Cantwell, Roland L. Hodges, JoAnn Hoskins, Stephen W. Queener, Paul L. Skatrud
  • Patent number: 6008041
    Abstract: The present invention provides the cDNA sequence encoding bovine dipeptidylaminopeptidase 1. The invention demonstrates that bovine DAP 1 coded by a single cDNA. The mature protein is derived from a single polypeptide consisting of a signal peptide, and a major polypeptide which is processed to generate the a subunit, b subunit and g subunit.
    Type: Grant
    Filed: May 2, 1997
    Date of Patent: December 28, 1999
    Assignee: Eli Lilly and Company
    Inventors: Christopher Carl Frye, Charles Lee Hershberger, Haichao Zhang
  • Patent number: 5945320
    Abstract: A DNA molecule isolated from Streptomyces ambofaciens encodes the multi-functional proteins which direct the synthesis of the polyketide platenolide.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: August 31, 1999
    Assignee: Eli Lilly and Company
    Inventors: Stanley G. Burgett, Stuart A. Kuhstoss, Ramachandra N. Rao, Mark A. Richardson, Paul R. Rosteck, Jr.
  • Patent number: 5876991
    Abstract: A DNA molecule isolated from Streptomyces fradiae encodes the multi-functional proteins which direct the synthesis of the polyketide tylactone.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: March 2, 1999
    Assignee: Eli Lilly and Company
    Inventors: Bradley S. DeHoff, Stuart A. Kuhstoss, Paul R. Rosteck, Jr., Kimberly L. Sutton
  • Patent number: 5874103
    Abstract: An aqueous base suspension concentrate of an ionophore antibiotic or ionophore antibiotics capable of aqueous dilution (if desired) and capable (with or without such aqueous dilution) of being orally administered to an animal (eg; by drenching), said concentration comprising(I) at least one ionophore antibiotic in (II) an aqueous system containing( ) a wetting and/or surfactant agent(ii) an antifreeze agent or agents in which the ionophore antibiotic or antibiotics is or are no more than sparingly soluble,(iii) a suspension agent,(iv) optionally an antifoam agent or system,(v) optionally a preservative,(vi) optionally a de-bittering agent,(vii) optionally a pH buffering system, and(viii) water.
    Type: Grant
    Filed: July 23, 1996
    Date of Patent: February 23, 1999
    Assignee: Eli Lilly and Company
    Inventors: Derek George Moore, Lionel Barry Lowe, Kevin Charles Palmer, Kim Ewing Melville Agnew
  • Patent number: 5824496
    Abstract: The present invention provides a method for preventing the accumulation of aberrant expression vectors during fermentation processes which rely on the expression of an expression vector coded gene for production of a polypeptide product of interest. Antibiotics are added at approximately the time at which product expression begins.
    Type: Grant
    Filed: August 10, 1995
    Date of Patent: October 20, 1998
    Assignee: Eli Lilly and Company
    Inventor: William L. Muth
  • Patent number: 5821331
    Abstract: The present invention provides a group of novel compounds that inhibit the proteolytic activity of 3C proteases which are found in picornaviruses, particularly rhinoviruses. In picornaviruses the RNA genome is translated into a single large viral polyprotein precursor. The precursor demonstrates auto-proteolytic activity, cleaving itself into mature viral gene products. Therefore, compounds of the current invention are particularly useful in treating picornaviral infections by interrupting the processing of the viral gene products into mature and infectious viral particles. The current invention also provides a novel process the preparation of compounds of the current invention. The process entails the selective reduction of an imide intermediate representing a marked improvement over processes known in the art for making peptidyl-aldehydes.
    Type: Grant
    Filed: February 8, 1996
    Date of Patent: October 13, 1998
    Assignee: Eli Lilly and Company
    Inventors: Marlys Hammond, Stephen W. Kaldor
  • Patent number: 5714363
    Abstract: Deacetoxycephalosporin C hydroxylase is obtained in purified form from crude cell-free extracts via chromatography over a weak anionic exchange resin, ammonium sulfate fractionation, gel filtration, hydroxylapatite chromatography, and FPLC. The enzyme is obtained in >90% purity by further gel filtration and a second FPLC. The 28-residue amino-terminal sequence of hydroxylase is provided as well as a 9-residue amino-terminal sequence of an internal sequence and a 3-residue carboxy-terminal sequence. In addition to the efficient conversion of DAOC to DAC, the hydroxylase provided herein converts 7.beta.-(.alpha.-aminoadipamido)-3-exomethylenecepham-4-carboxylic acid to DAC.
    Type: Grant
    Filed: April 23, 1992
    Date of Patent: February 3, 1998
    Assignee: Eli Lilly and Company
    Inventors: Wu-Kuang Yeh, Joe E. Dotzlaf
  • Patent number: 5691385
    Abstract: .beta.-Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: November 25, 1997
    Assignee: Eli Lilly and Company
    Inventors: David B. Anderson, Klaus K. Schmiegel, Edward L. Veenhuizen
  • Patent number: 5686413
    Abstract: Combined administration of a growth hormone related substance and ractopamine, cimaterol, clenbuterol, L-644,969, or albuterol to swine provides improved growth feed efficiency, and carcass quality. Administration of ractopamine, cimaterol, clenbuterol, L-644,969, or albuterol to swine that also receive growth hormone related substance reduces greater than normal blood sugar and insulin levels.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: November 11, 1997
    Assignee: Eli Lilly and Company
    Inventors: David B. Anderson, D. Jay Jones, Alvin L. Melliere
  • Patent number: 5677423
    Abstract: A process for removing .beta.-hydroxy groups from .beta.-hydroxy-containing compounds is disclosed. The process involves the use of a retro-aldol-promoting reagent selected from the group of trimethylamine-N-oxide, triethylamine-N-oxide, trimethylamine-N-oxide-hydrate, and trimethylamine-hydrate and requires dissolution of the substrate in an aprotic solvent and reaction under elevated temperatures. The process is broadly applicable to a variety of substrates including complex cyclic peptides, linear peptides, and non-peptides.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: October 14, 1997
    Assignee: Eli Lilly and Company
    Inventor: Michael J. Rodriguez
  • Patent number: 5670485
    Abstract: The present invention is directed to anticoccidial methods, animal feed premixes, and animal feeds, employing a specified o-phenylenediamine or benzimidazole. The present invention is also directed to anticoccidial methods, animal feed premixes, and animal feeds employing two active agents. In such combined therapy, a first substance is a polyether antibiotic, and the second substance is a designated, benzimidazoline.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: September 23, 1997
    Assignee: Eli Lilly and Company
    Inventor: George O. P. O'Doherty
  • Patent number: 5658755
    Abstract: Heterologous extra-cellular expression of recombinant proteins in soluble functional form is desirable because of the ease associated with purification of the secreted proteins and avoidance of the need for cell extraction and protein refolding procedures. The present invention provides DNA sequences of the naturally-occurring phthalyl amidase gene isolated from Xanthobacter agilis that control transcription, translation, and extra-cellular secretion of proteins in Streptomyces lividans. These DNA sequences can be used in a method for extra-cellular expression of a wide variety of proteins in soluble functional form.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: August 19, 1997
    Assignee: Eli Lilly and Company
    Inventors: Stephen W. Queener, Joseph M. Zock
  • Patent number: 5650397
    Abstract: The present invention is directed to anticoccidial methods, animal feed premixes, and animal feeds, employing a specified o-phenylenediamine or benzimidazole. The present invention is also directed to anticoccidial methods, animal feed premixes, and animal feeds employing two active agents. In such combined therapy, a first substance is a polyether antibiotic, and the second substance is a designated o-phenylenediamine, benzimidazole, or benzimidazoline.
    Type: Grant
    Filed: April 21, 1995
    Date of Patent: July 22, 1997
    Assignee: Eli Lilly and Company
    Inventor: George O. P. O'Doherty
  • Patent number: 5646275
    Abstract: 7.beta.-Amino-3-hydroxy-1-carba(1-dethia)-3-cephem-4-carboxylic acid esters are provided via cyclization of compounds of Formula IIA below. ##STR1## The 7.beta.-Amino-3-hydroxy-l-carba(1-dethia)-3-cephem-4-carboxylic acid esters are useful chiral intermediates in the synthesis of .beta.-lactam antibiotics.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: July 8, 1997
    Assignee: Eli Lilly and Company
    Inventors: John P. Gardner, Billy G. Jackson
  • Patent number: 5643967
    Abstract: .beta.-Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.
    Type: Grant
    Filed: March 18, 1993
    Date of Patent: July 1, 1997
    Assignee: Eli Lilly and Company
    Inventors: David B. Anderson, Klaus K. Schmiegel, Edward L. Veenhuizen, Ronald R. Tuttle
  • Patent number: 5637603
    Abstract: The present invention is directed to the use of disulfonyl methane compounds for the control of parasites in vertebrate animals.
    Type: Grant
    Filed: April 25, 1995
    Date of Patent: June 10, 1997
    Assignee: Eli Lilly and Company
    Inventor: David I. Wickiser
  • Patent number: 5635216
    Abstract: A composition of polyester microparticles containing bioactive polypeptide agents and methods for preparing the composition and administering bioactive agents. The composition comprises biocompatible, biodegradable microparticles having a polyester matrix and from about 5% to about 25% by weight of a biologically active, water-soluble polypeptide dispersed throughout the matrix, the polypeptide selected from the group consisting of growth hormone releasing factor, synthetic analogs of growth hormone releasing factor, pharmacologically active fragment thereof and somatogenin. The method for preparing the composition includes dissolving polyester in an organic solvent; suspending a biologically active agent in the polyester solution; emulsifying the suspension into an aqueous medium in which the agent is insoluble and evaporating the solvent from the emulsion to produce microparticles.
    Type: Grant
    Filed: December 16, 1993
    Date of Patent: June 3, 1997
    Assignee: Eli Lilly and Company
    Inventor: William W. Thompson
  • Patent number: 5635490
    Abstract: The present invention is directed to anticoccidial methods, animal feed premixes, and animal feeds, employing a specified o-phenylenediamine or benzimidazole. The present invention is also directed to anticoccidial methods, animal feed premixes, and animal feeds employing two active agents. In such combined therapy, a first substance is a polyether antibiotic, and the second substance is a designated o-phenylenediamine, benzimidazole, or benzimidazoline.
    Type: Grant
    Filed: May 26, 1995
    Date of Patent: June 3, 1997
    Assignee: Eli Lilly and Company
    Inventor: George O. P. O'Doherty
  • Patent number: 5631298
    Abstract: .beta.-Phenethanolamines are effective in promoting growth and improving feed efficiency and leanness in animals.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: May 20, 1997
    Assignee: Eli Lilly and Company
    Inventors: David B. Anderson, Edward L. Veenhuizen